The long-standing need to determine an effective medical treatment regimen with clinically
significant and relevant end-points to improve outcome for patients with idiopathic …

Idiopathic pulmonary fibrosis (IPF) is a challenging and frustrating disease for clinicians and
patients confronted with this clinical entity, since it is associated with a dismal, 3-yr median …

Idiopathic pulmonary fibrosis (IPF), also known as cryptogenic fibrosing alveolitis, is a
distinct form of interstitial lung disease of unknown etiology that is limited to the lung; it is …

Despite multiple clinical trials, there is no strong, definitive evidence in favor of any agent to
treat IPF. On the other hand, the placebo arms of these large trials have provided us with …

Randomised controlled clinical trials are fundamental in medicine to develop new effective
drugs and new therapeutic regimens and are the strength of evidence-based medicine …

Idiopathic pulmonary fibrosis (IPF) is a lethal form of idiopathic diffuse lung disorders for
which no current treatment is effective. The aim of the present study was to systematically …

Idiopathic pulmonary fibrosis (IPF) is increasingly recog-nised as a well-known clinical and
highly complex entity associated with poor prognosis and a median survival of 3–5 yrs after …

The past decade has seen substantial progress in understanding the pathobiology, natural
history, and clinical significance of idiopathic pulmonary fibrosis (IPF), culminating in the …

Idiopathic pulmonary fibrosis (IPF) represents one of the most challenging diseases for chest
physicians. The diagnostic process is complex and requires close interaction with different …

Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive lung disease in most cases,
and effective treatment is still lacking. This review examines the current status of treatment …